Literature DB >> 18253057

Brain-derived neurotropic factor/TrkB signaling in the pathogenesis and novel pharmacotherapy of schizophrenia.

Anilkumar Pillai1.   

Abstract

The role of neurotropins, predominantly brain-derived neurotropic factor (BDNF), has been implicated in the pathophysiology as well as treatment outcome of schizophrenia. Both human and rodent studies indicate that the beneficial effects of antipsychotic drugs are mediated, at least in part, through BDNF and its receptor, TrkB. This review will discuss the available data on the levels of BDNF and TrkB in subjects with schizophrenia and in animals with and without conventional antipsychotics. The data concerning the impact of the antipsychotic drugs on BDNF/TrkB signaling will also be discussed. More importantly, this review will provide future perspective on BDNF/TrkB signaling as a novel molecular target to correct the pathogenesis and improve the long-term clinical outcome by treatments with conventional and adjunctive drugs. (c) 2008 S. Karger AG, Basel.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18253057     DOI： 10.1159/000111562

Source DB:  PubMed          Journal:  Neurosignals        ISSN： 1424-862X


  40 in total

Review 1.  Brain-derived neurotrophic factor and neuropsychiatric disorders.

Authors:  Anita E Autry; Lisa M Monteggia
Journal:  Pharmacol Rev       Date:  2012-03-08       Impact factor: 25.468

2.  Pharmacological activation of group-II metabotropic glutamate receptors corrects a schizophrenia-like phenotype induced by prenatal stress in mice.

Authors:  Francesco Matrisciano; Patricia Tueting; Stefania Maccari; Ferdinando Nicoletti; Alessandro Guidotti
Journal:  Neuropsychopharmacology       Date:  2011-11-16       Impact factor: 7.853

Review 3.  Current Neurogenic and Neuroprotective Strategies to Prevent and Treat Neurodegenerative and Neuropsychiatric Disorders.

Authors:  I M Carvalho; P B Coelho; P C Costa; C S Marques; R S Oliveira; D C Ferreira
Journal:  Neuromolecular Med       Date:  2015-09-15       Impact factor: 3.843

4.  Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans.

Authors:  Deepak Cyril D'Souza; Brian Pittman; Edward Perry; Arthur Simen
Journal:  Psychopharmacology (Berl)       Date:  2008-09-21       Impact factor: 4.530

5.  Glucocorticoid regulates TrkB protein levels via c-Cbl dependent ubiquitination: a decrease in c-Cbl mRNA in the prefrontal cortex of suicide subjects.

Authors:  Chirayu Pandya; Ammar Kutiyanawalla; Gustavo Turecki; Anilkumar Pillai
Journal:  Psychoneuroendocrinology       Date:  2014-04-06       Impact factor: 4.905

6.  Association between BDNF Val66Met polymorphism and cognitive performance in antipsychotic-naïve patients with schizophrenia.

Authors:  Weihong Lu; Chen Zhang; Zhenghui Yi; Zezhi Li; Zhiguo Wu; Yiru Fang
Journal:  J Mol Neurosci       Date:  2012-04-03       Impact factor: 3.444

Review 7.  BDNF-TrkB signaling and neuroprotection in schizophrenia.

Authors:  Chirayu D Pandya; Ammar Kutiyanawalla; Anilkumar Pillai
Journal:  Asian J Psychiatr       Date:  2012-11-03

Review 8.  Cannabis and psychosis/schizophrenia: human studies.

Authors:  Deepak Cyril D'Souza; Richard Andrew Sewell; Mohini Ranganathan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-16       Impact factor: 5.270

Review 9.  Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophrenia.

Authors:  Yael Chertkow; Orly Weinreb; Moussa B H Youdim; Henry Silver
Journal:  J Neural Transm (Vienna)       Date:  2009-07-04       Impact factor: 3.575

10.  Influence of brain-derived neurotrophic factor on pathfinding of dentate granule cell axons, the hippocampal mossy fibers.

Authors:  Makoto Tamura; Naohiro Tamura; Takamitsu Ikeda; Ryuta Koyama; Yuji Ikegaya; Norio Matsuki; Maki K Yamada
Journal:  Mol Brain       Date:  2009-01-31       Impact factor: 4.041
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.